Prosecution Insights
Last updated: November 12, 2026
Application No. 18/582,785

APTAMER-siRNA FUSIONS

Non-Final OA §103
Filed
Feb 21, 2024
Priority
Dec 14, 2020 — GB 2019692.9 +2 more
Examiner
POLIAKOVA-GEORGAN, EKATERINA
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Apterna Limited
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
82%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
440 granted / 692 resolved
+3.6% vs TC avg
Strong +18% interview lift
Without
With
+18.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
62 currently pending
Career history
763
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-10, in the reply filed on 08/24/2026 is acknowledged. Claims 11-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/24/2026. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Saertrom (WO 2015/075557, May 2015) and in further view of Gryaznov et al (WO 2019/053661, March 2019). Saertrom teaches siRNA targeting C/EBPβ of SEQ ID NO: 29 (see Table 3 on page 26), which is 100% identical to instant SEQ ID NOs: 9 and 46 and can be used for treatment of hepatocellular carcinoma (see paragraph [00266]). Saertrom teaches that siRNA can comprise 2' ribose modifications (see paragraph [00134]) and can be delivered with the help of GalNAc (see paragraph [00203]). Saertrom teach pharmaceutical compositions comprising the siRNA and pharmaceutically acceptable carrier (see paragraphs [00152, 0096]). Saertrom does not teach siRNA of SEQ ID NO: 29 comprising 3 GalNAc residues conjugated via aminohexyl linker. Gryaznov teach GalNAc moieties for targeting oligonucleotides to hepatocytes (see paragraph [0007]). Such moieties can be conjugated using aminohexyl (C6-NH2) linker (see paragraph [0008]) and can comprise 3 GalNAc residues (see structures on page 6 and page 64). It would have been obvious to one of the ordinary skill in the art before the effective filing date of the claimed invention to conjugate siRNA taught by Saertrom to GalNAc moieties as taught by Gryaznov, arriving at instant invention. One of the ordinary skill in the art would be motivated to do so, because the siRNA of Saertrom is intended for treatment of liver cancer, therefore it is helpful to conjugate it with GalNAc moieties targeting such siRNA to liver cells as taught by Gryaznov, improving such siRNA delivery and activity. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to EKATERINA POLIAKOVA whose telephone number is (571)270-5257. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at (571)272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EKATERINA POLIAKOVA-GEORGANTAS/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Feb 21, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781274
Novel Replicase Cycling Reaction (RCR) and the Related RdRP-Binding Site Designs Thereof
3y 1m to grant Granted Nov 03, 2026
Patent 12781232
BACTERIAL CONTINUOUS EVOLUTION SYSTEM, ORTHOGONAL ERROR-PRONE DNA POLYMERASE, AND CONTINUOUS EVOLUTION METHOD
2y 11m to grant Granted Nov 03, 2026
Patent 12774310
POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
3y 5m to grant Granted Oct 27, 2026
Patent 12767946
OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
6y 7m to grant Granted Oct 20, 2026
Patent 12735705
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3
3y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
82%
With Interview (+18.5%)
Low
PTA Risk
Based on 692 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month